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Abstract
Background: Patients with ankylosing spondylitis (AS), who by definition have radiographic sacroiliitis, typically
experience symptoms for a decade or more before being diagnosed. Yet, even patients without radiographic
sacroiliitis (i.e., nonradiographic axial spondyloarthritis [nr-axSpA]) report a significant disease burden. The primary
objective of this study was to estimate the prevalence and clinical characteristics of nr-axSpA among patients with
inflammatory back pain (IBP) in rheumatology clinics in a number of countries across the world. A secondary
objective was to estimate the prevalence of IBP among patients with chronic low back pain (CLBP).
Methods: Data were collected from 51 rheumatology outpatient clinics in 19 countries in Latin America, Africa,
Europe, and Asia. As consecutive patients with CLBP (N = 2517) were seen by physicians at the sites, their clinical
histories were evaluated to determine whether they met the new Assessment of SpondyloArthritis international
Society criteria for IBP. For those who did, their available clinical history (e.g., family history, C-reactive protein [CRP]
levels) was documented in a case report form to establish whether they met criteria for nr-axSpA, AS, or other IBP.
Patients diagnosed with nr-axSpA or AS completed patient-reported outcome measures to assess disease activity
and functional limitations.
Results: A total of 2517 patients with CLBP were identified across all sites. Of these, 974 (38.70 %) fulfilled the
criteria for IBP. Among IBP patients, 29.10 % met criteria for nr-axSpA, and 53.72 % met criteria for AS. The
prevalence of nr-axSpA varied significantly by region (p < 0.05), with the highest prevalence reported in Asia (36.
46 %) and the lowest reported in Africa (16.02 %). Patients with nr-axSpA reported mean ± SD Ankylosing
Spondylitis Disease Activity Scores based on erythrocyte sedimentation rate and CRP of 2.62 ± 1.17 and 2.52 ± 1.21,
respectively, indicating high levels of disease activity (patients with AS reported corresponding scores of 2.97 ± 1.13
and 2.93 ± 1.18). Similarly, the overall Bath Ankylosing Spondylitis Disease Activity Index score of 4.03 ± 2.23 for
patients with nr-axSpA (4.56 ± 2.17 for patients with AS) suggested suboptimal disease control.
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Conclusions: These results suggest that, in the centers that participated in the study, 29 % of patients with IBP met
the criteria for nr-axSpA and 39 % of patients with CLBP had IBP. The disease burden in nr-axSpA is substantial and
similar to that of AS, with both groups of patients experiencing inadequate disease control. These findings suggest
the need for early detection of nr-axSpA and initiation of available treatment options to slow disease progression
and improve patient well-being.
Keywords: Nonradiographic axial SpA, Ankylosing spondylitis, Prevalence, Inflammatory low back pain, Chronic low
back pain
Background
Spondyloarthritis (SpA) is a constellation of chronic in-
flammatory conditions that includes ankylosing spondyl-
itis (AS), reactive arthritis, enteropathic arthritis, and
psoriatic arthritis, among others [1]. Collectively, the
prevalence of SpA varies between 0.5 % and 2 %, making
it approximately as common as rheumatoid arthritis [1].
On the basis of their clinical presentation, patients with
SpA can be categorized as having axial SpA, in which
the spine is predominantly affected, or peripheral SpA,
in which the extremities are predominantly affected
[2, 3]. According to the 2009 criteria of the Assessment of
SpondyloArthritis international Society (ASAS), axial SpA
is further categorized into nonradiographic axial SpA (nr-
axSpA) and AS, in which the major distinguishing feature
is the presence (for AS) or absence (for nr-axSpA) of
radiographic sacroiliitis [2, 3].
Approximately 10 % of patients with nr-axSpA develop
AS within 2 years and 60 % develop AS within 10 years
[4]. Although patients with nr-axSpA may have inflam-
mation detectable by magnetic resonance imaging [5, 6],
early detection of axial SpA poses a major challenge to
many physicians [2, 3]. Indeed, patients may experience
symptoms for a decade or more before receiving a diag-
nosis [1]. Patients with axial SpA also report a number
of impairments in physical functioning and spinal mobil-
ity, experience high rates of disability, and contribute to
high societal costs [4]. Timely identification of axial SpA
may potentially lead to earlier and more effective inter-
vention to delay disease progression [5].
The majority of axial SpA studies have been conducted
in Europe, the United States, and Mexico, with informa-
tion extremely limited in the emerging countries of Latin
America, Africa, Central and Eastern Europe, and Asia.
The general population prevalence of axial SpA in
Europe has been estimated to be between 0.08 %
(France) and 0.49 % (Turkey) [6]. The prevalence is
slightly higher in the Americas, with researchers in
Mexico and the United States reporting rates of 0.60 %
and 0.90–1.40 %, respectively [6, 7].
Many of the studies cited above have been focused on
AS or axial SpA, leading to a lack of epidemiological and
clinical data specific to nr-axSpA. Indeed, even the
proportion of axial SpA patients with nr-axSpA is un-
known, as estimates vary considerably, ranging from
23 % to 80 % in a recent review of patients with axial
SpA [4]. In part, this is due to different methods of as-
sessment and the fact that these studies were not specif-
ically designed to follow patients with undifferentiated
SpA and nr-axSpA [4].
The lack of data on nr-axSpA and AS is even more
pronounced in emerging countries in Latin America,
Europe, Africa, and Asia. The primary objective of this
study was to provide prevalence estimates on the pres-
ence of nr-axSpA among patients with inflammatory
back pain (IBP) in rheumatology clinics across a number
of emerging countries. In this study, we also sought to
describe the clinical characteristics associated with both
nr-axSpA and AS. A secondary objective was to estimate
the prevalence of IBP among patients with chronic low
back pain (CLBP), given that IBP represents an increas-




A noninterventional, cross-sectional study was con-
ducted to estimate the prevalence of nr-axSpA among
patients with IBP in 51 rheumatology outpatient clinics
from 19 countries in Latin America (Colombia, Costa
Rica, Mexico, and Peru), Europe inclusive of western
Asia (Hungary, Israel, Kazakhstan, Poland, Romania,
Russia, and Turkey), Africa (Algeria, Morocco, and
South Africa), and Asia focused on southern and eastern
Asia (Bangladesh, China, India, Malaysia, and Taiwan).
Patient recruitment took place from January through
December 2014. The protocol and study materials received
institutional review board approval at each participating
site; the specific sites are listed in the Acknowledgements
section.
Consecutive patients with CLBP were seen by partici-
pating physicians at the study sites and were evaluated
clinically to determine whether they met the criteria for
IBP. Patients who met 2009 ASAS criteria for IBP had
their clinical histories further evaluated to determine their
eligibility for the medical record abstraction portion of this
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study. The inclusion criteria were age ≥18 years,
CLBP ≥3 months, and four of five of the following param-
eters: age of onset <40 years, insidious onset, improve-
ment with exercise, no improvement with rest, and pain
at night. The exclusion criteria were noninflammatory
back pain, a condition that could mimic IBP (e.g., fibro-
myalgia), the presence of a neuropathic component, unex-
plained weight loss of >10 kg within the past 6 months,
persistent fever, urinary incontinence or retention, saddle
anesthesia, decreased anal sphincter tone or fecal incon-
tinence, bilateral lower extremity weakness or numbness,
or progressive neurologic deficit.
For patients who met the appropriate inclusion criteria
and provided written informed consent, a medical rec-
ord abstraction using a case report form (CRF) was per-
formed to determine whether the patients met the
criteria for AS, nr-axSpA, or other forms of IBP (“other
IBP” hereafter) based on ASAS criteria for axial SpA and
the Modified New York (Modified NY) criteria for AS
(Fig. 1). More specifically, patients who did not meet
ASAS criteria were classified as having other IBP.
Patients who met ASAS criteria for axial SpA but did
not meet Modified NY criteria were classified as having
nr-axSpA. Patients who met both ASAS criteria for axial
SpA and Modified NY criteria were classified as having
AS.
Patients who were diagnosed with AS or nr-axSpA
were provided with a brief survey to evaluate their
patient-reported outcomes (PROs). It is important to
note that diagnosed refers to the physician’s classification
of that patient as indicated in the medical record. It is
not known what information was used to make this as-
sessment. The classification of patients based on ASAS
criteria for axial SpA and Modified NY criteria for AS, as
described above, was an analytical exercise performed by
the authors after data collection; it was not conducted in
real time as patients were enrolled into the study. As a
result, the study depended upon the physician’s classifi-
cation (referred hereafter as diagnosis to distinguish the
methods) in order to identify patients eligible to receive
the survey, even if this differed from our methods of
classification using the ASAS criteria for axial SpA and
the Modified NY criteria for AS. This survey was com-
pleted entirely by the patient in the waiting room to
avoid any influence from the investigator. At the end








• Crohn’s disease/ulcerative colitis
• Good response to NSAIDs
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Fig. 1 Summary of inflammatory back pain (IBP) group classifications. AS ankylosing spondylitis, ASAS Assessment of SpondyloArthritis
international Society, axSpA axial spondyloarthritis, CRP C-reactive protein, HLA-B27 human leukocyte antigen B27, Modified NY criteria Modified
New York criteria for ankylosing spondylitis, nr-axSpA nonradiographic axial spondyloarthritis, NSAID nonsteroidal anti-inflammatory drug,
SpA spondyloarthritis
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collected on-site and checked for completion, with the
exception of the patient questionnaire, which remained
confidential.
Measures
The CRF assessed information on each patient’s demo-
graphics (age, sex, race/ethnicity), general health history
(body mass index [BMI], years of experienced CLBP), and
disease history (human leukocyte antigen B27 [HLA-B27]
test results, C-reactive protein [CRP] results, erythrocyte
sedimentation rate [ESR] results, family history, nonsteroi-
dal anti-inflammatory drug [NSAID] response). The patient
survey included the Ankylosing Spondylitis Disease
Activity Score (ASDAS; both ESR and CRP versions),
Bath Ankylosing Spondylitis Disease Activity Index (BAS-
DAI), Bath Ankylosing Spondylitis Functional Index
(BASFI), and Bath Ankylosing Spondylitis Metrology
Index (BASMI).
Statistical analysis
The analysis of the primary objectives (prevalence and
clinical characteristics of nr-axSpA) was focused on pa-
tients with IBP who met the inclusion or exclusion cri-
teria described above. The analysis of the secondary
objective (prevalence of IBP among patients with CLBP)
was focused on all patients with CLBP. Frequencies, per-
centages, and 95 % CIs were reported for binary and/or
categorical variables. Counts, means, and SDs were re-
ported for continuous variables. Statistical differences
across geographical regions were analyzed using chi-
square tests and one-way analysis of variance for cat-
egorical and continuous variables, respectively.
Results
Prevalence of nr-axSpA overall, by region, and by sex
A total of 2517 patients with CLBP were identified across
all sites (Fig. 2). Of these, 974 (38.70 %) fulfilled the criteria
for IBP and were advanced to the CRF portion of the study
for assessment of IBP group status (i.e., nr-axSpA, AS, or
other IBP). Overall, 29.10 % (95 % CI 26.15–32.05 %) of pa-
tients with IBP met the criteria for nr-axSpA (Table 1). The
prevalence of AS among patients with IBP was 53.72 %
(95 % CI 50.48–56.96 %). The prevalence of nr-axSpA var-
ied significantly by region (p < 0.05), with the highest preva-
lence reported in Asia (36.46 %, 95 % CI 31.64–41.28 %)
and the lowest reported in Africa (16.02 %, 95 % CI 11.00–
21.04 %). The prevalence of nr-axSpA was similar among
males (28.74 %, 95 % CI 25.07–32.41 %) and females
(29.75 %, 95 % CI 24.77–34.74 %) with IBP.
Demographic characteristics of patients with nr-axSpA
Patients with nr-axSpA had a mean age of 34.75 years (SD
10.03); 36.47 % were female, and 55.64 % were white
(Table 2). These figures contrasted with patients with AS,
who had a mean age of 39.03 years (SD 11.38); 28.72 %
were female, and 68.23 % were white. Minimal regional
differences were observed with respect to the demo-
graphic characteristics of patients with nr-axSpA (Table 3).
Patients with nr-axSpA were oldest in Africa (36.67 years)
and youngest in Asia (33.24 years) (p < 0.05); however, no
differences in sex, BMI, years since CLBP presentation, or
age of IBP onset were observed across regions.
Clinical characteristics of patients with nr-axSpA
Patients with nr-axSpA experienced CLBP for 6.32 ±
7.61 years (compared with 10.91 years for patients with
Fig. 2 Study flowchart. AS ankylosing spondylitis, ASAS Assessment of SpondyloArthritis international Society, CLBP chronic low back pain, CRF
case report form, IBP inflammatory back pain, Modified NY criteria Modified New York criteria for ankylosing spondylitis, nr-axSpA nonradiographic
axial spondyloarthritis, SpA spondyloarthritis
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AS) (Table 2). HLA-B27 test results were available for
71.05 % of those with nr-axSpA, and 82.78 % of them
had a positive test result (Table 4). Proportions of
68.14 % and 37.30 % of patients with nr-axSpA had ele-
vated CRP and ESR values, respectively. For context,
proportions of 77.20 % and 48.92 % of patients with AS
had elevated CRP and ESR values, respectively.
Several clinical characteristics varied across regions
among those with nr-axSpA (Table 5). Patients in
Europe were the most likely to have a positive HLA-B27
test result (84.85 %), and patients in Asia were the least
likely (62.24 %) (p < 0.05). Patients in Asia were the most
likely to have an elevated ESR value (48.89 %), and pa-
tients in Europe were the least likely (20.48 %) (p < 0.05).
No differences in family history or NSAID response
were observed.
Delay from IBP and CLBP to nr-axSpA or AS diagnosis
For patients who received a diagnosis of nr-axSpA, there
was a mean delay of 5.21 ± 7.69 years between the pres-
entation of IBP and diagnosis (Table 4). There was a
mean delay of 6.48 ± 8.53 years between the presentation
of IBP and diagnosis for patients with AS.
Patient-reported outcomes in nr-axSpA and AS
The mean disease activity levels for patients with nr-
axSpA were 2.62 ± 1.17 and 2.52 ± 1.21 for the ESR and
CRP versions of the ASDAS, respectively, suggesting a
high level of disease activity (i.e., ≥2.1) (Table 6). The
mean overall BASDAI score was 4.03 ± 2.32 for patients
with nr-axSpA, indicating a suboptimal level of disease
control. Finally, BASFI score (3.20 ± 2.47) and BASMI
scores (11-point version 2.41 ± 1.54, 3-point version
1.62 ± 1.51, linear function version 3.71 ± 2.77) indicated
a significant burden for patients with nr-axSpA and were
relatively comparable to BASFI score (4.09 ± 2.59) and
BASMI scores (11-point version 4.09 ± 2.06, 3-point ver-
sion 3.40 ± 2.25, linear function version 4.77 ± 2.38) for
patients with AS. No differences in PRO measures were
observed across regions, with the exception of the 3-point
BASMI version (Africa = 2.59 ± 1.52, Europe = 1.46 ± 1.53,
Asia = 1.30 ± 1.36; p < 0.05).
Discussion
In this study, 39 % of patients referred to rheumatology
clinics with CLBP met the ASAS criteria for IBP. Further,
29 % of patients with IBP met the criteria for nr-axSpA.
The proportion of axial SpA patients with nr-axSpA was
within the range (23–80 %) reported in the literature
[4, 8], though on the lower end of prior estimates.
Our data suggest a higher percentage of males among
patients with nr-axSpA (64 %) relative to the percentages
in other published noninterventional studies (34–50 %)
[9, 10] and most clinical trials (48–64 %) [11–16]. There
were a number of methodological differences across
these studies (e.g., inclusion and exclusion criteria, coun-
try), but it is unclear which of these factors would help
to explain the differences in results. Further research is
necessary.
We found that patients with nr-axSpA were the youn-
gest, and they experienced CLBP for the shortest dur-
ation at slightly over 6 years compared with nearly
11 years for patients with AS. Although no age differ-
ences were found in past literature reviews between pa-
tients with nr-axSpA and those with AS [4, 8], several
prior studies have found a longer symptom duration for
patients with AS [4–8, 10, 17, 18]. This is to be
Table 1 Prevalence of nonradiographic axial spondyloarthritis among patients with inflammatory back pain across geographic
regions
Total Latin America Africa Europe Asia p Value
Overall sample
Number of patients 914 26 206 298 384
nr-axSpA, n (%) 266 (29.10 %) 5 (19.23 %) 33 (16.02 %) 88 (29.53 %) 140 (36.46 %) <0.001
95 % CI (26.15–32.05) (4.05–34.41) (11.00–21.04) (24.34–34.72) (31.64–41.28)
Among males
Number of patients 588 12 116 204 256
nr-axSpA, n (%) 169 (28.74 %) 4 (33.33 %) 18 (15.52 %) 57 (27.94 %) 90 (35.16 %) <0.001
95 % CI (25.07–32.41) (6.58–60.08) (8.91–22.13) (21.77–34.12) (29.29–41.02)
Among females
Number of patients 326 14 90 94 128
nr-axSpA, n (%) 97 (29.75 %) 1 (7.14 %) 15 (16.67 %) 31 (32.98 %) 50 (39.06 %) <0.001
95 % CI (24.77–34.74) (0.00–20.70) (8.93–24.41) (23.42–42.53) (30.57–47.56)
nr-axSpA nonradiographic axial spondyloarthritis
The p values represent the omnibus statistical comparison of percentages across geographic regions
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Table 2 Demographic characteristics of nonradiographic axial spondyloarthritis, ankylosing spondylitis, and other inflammatory back
pain patients
Total (N = 914) nr-axSpA (n = 266) AS (n = 491) Other IBP (n = 157) p Value
Sex <0.001
Male, n (%) 588 (64.33 %) 169 (63.53 %) 350 (71.28 %) 69 (43.95 %)
95 % CI (61.22–67.44) (57.74–69.33) (67.27–75.29) (36.17–51.73)
Female, n (%) 326 (35.67 %) 97 (36.47 %) 141 (28.72 %) 88 (56.05 %)
95 % CI (32.56–38.78) (30.67–42.26) (24.71–32.73) (48.27–63.83)
Sex <0.001
Male, n (row %) 588 (100.00 %) 169 (28.75 %) 350 (59.52 %) 69 (11.73 %)
95 % CI (25.08–32.41) (55.54–63.50) (9.13–14.34)
Female, n (row %) 326 (100.00 %) 97 (29.75 %) 141 (43.25 %) 88 (26.99 %)
95 % CI (24.78–34.73) (37.86–48.64) (22.17–31.82)
Age, years, mean ± SD 38.68 ± 12.02 34.75 ± 10.03 39.03 ± 11.38 44.26 ± 14.48 <0.001
Race/ethnicity <0.001
White, n (%) 596 (65.21 %) 148 (55.64 %) 335 (68.23 %) 113 (71.97 %)
95 % CI (62.11–68.30) (49.66–61.62) (64.10–72.35) (64.94–79.01)
Asian, n (%) 116 (12.69 %) 55 (20.68 %) 55 (11.20 %) 6 (3.82 %)
95 % CI (10.53–14.85) (15.80–25.55) (8.41–14.00) (0.82–6.83)
Black, n (%) 12 (1.31 %) 2 (0.75 %) 2 (0.41 %) 8 (5.10 %)
95 % CI (0.57–2.05) (0.00–1.79) (0.00–0.97) (1.65–8.54)
Unknown, n (%) 190 (20.79 %) 61 (22.93 %) 99 (20.16 %) 30 (19.11 %)
95 % CI (18.15–23.42) (17.87–27.99) (16.61–23.72) (12.95–25.27)
BMI category 0.024
Underweight, n (%) 55 (6.02 %) 12 (4.51 %) 38 (7.74 %) 5 (3.18 %)
95 % CI (4.47–7.56) (2.01–7.01) (5.37–10.11) (0.43–5.94)
Normal weight, n (%) 455 (49.78 %) 150 (56.39 %) 236 (48.07 %) 69 (43.95 %)
95 % CI (46.53–53.03) (50.42–62.36) (43.64–52.49) (36.17–51.73)
Overweight, n (%) 279 (30.53 %) 78 (29.32 %) 146 (29.74 %) 55 (35.03 %)
95 % CI (27.53–33.52) (23.84–34.8) (25.68–33.79) (27.56–42.51)
Obese, n (%) 121 (13.24 %) 24 (9.02 %) 70 (14.26 %) 27 (17.20 %)
95 % CI (11.04–15.44) (5.57–12.47) (11.16–17.36) (11.28–23.11)
Unknown, n (%) 4 (0.44 %) 2 (0.75 %) 1 (0.20 %) 1 (0.64 %)
95 % CI (0.01–0.87) (0.00–1.79) (0.00–0.60) (0.00–1.88)
Years since CLBP presentation <0.001
Number of patients 808 232 435 141
Mean ± SD, years 9.09 ± 9.07 6.32 ± 7.61 10.91 ± 9.37 8.05 ± 9.10
Age of IBP onset <0.001
Number of patients 908 264 488 156
Mean ± SD, years 28.8 ± 9.7 27.8 ± 7.3 27.0 ± 7.7 36.2 ± 14.2
Abbreviations: AS ankylosing spondylitis, BMI body mass index, CLBP chronic low back pain, CRF case report form, IBP inflammatory back pain, nr-axSpA
nonradiographic axial spondyloarthritis
Broad race categories (white vs. black vs. Asian vs. unknown) were created on the basis of physician-reported patient ethnicity: white = Indian, Indo-Aryan,
Dravidian, Bengali, Arab, Iranian, white, Jewish, Azeri, Mestizo, Amerindian, Berber; black = black, mulatto, mulato, zambo, black African, colored; Asian = Han
Chinese, non-Han Chinese, Taiwanese, Chinese, aborigine, Malay, indigenous, mongoloid, Asian; unknown = other or missing
The p values represent the omnibus statistical comparison of percentages (or means) across IBP groups based on the chi-square (or F-test) values
“Other IBP” refers to patients who did not meet the Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis
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expected, given that nr-axSpA and AS likely represent a
progression in the spectrum of the same disease.
Among patients who had been diagnosed with nr-
axSpA, there was a delay of approximately 5 years
between presentation of IBP and diagnosis. This
finding was consistent with the study by Poddubnyy
and colleagues, who which also found a gap of
slightly more than 5 years between back pain and
the assessment of nr-axSpA [17]. However, it should
be noted that many patients who met the criteria for
nr-axSpA were not diagnosed even after this period
of several years, reinforcing the importance of in-
creasing the awareness of, and adherence to, ASAS
classification criteria for timely diagnosis and initi-
ation of treatment.
Among those with HLA-B27 test results, 83 % of the
patients with nr-axSpA had positive results. This finding
is consistent with what was summarized by Boonen et
al. [4] and reported directly in two recent noninterven-
tional studies (73 % in a study by Poddubnyy and col-
leagues [11] and 86 % in a study by Kiltz and colleagues
[18]. Over two-thirds (68 %) of patients with nr-axSpA
had elevated CRP values (≥3.5 mg/L), which was nearly
as high as the percentage of patients with AS who had
elevated CRP values (77 %).
Data derived from the patient surveys demonstrated a
high level of disease activity and a suboptimal level of
disease control, as assessed using the ASDAS and BAS-
DAI, respectively, for patients with nr-axSpA. It is im-
portant to note that even patients with nr-axSpA [19],
who are in an earlier phase in the course of axial SpA,
exhibited a significant burden that was comparable to
that of patients with AS. BASDAI scores in our study
were lower than those reported in a review of clinical
trial results of biologic treatments [8], suggesting a less
severe patient-reported burden in this real-world patient
population. The levels of functional impairment (BASFI)
and limitations (BASMI) were comparable to those re-
ported for clinical trial populations [4]. Given the early
age of onset for nr-axSpA, these impairment data sug-
gest that patients can experience a substantial level of
burden for many years. This further illustrates the im-
portance of identifying patients early in order to slow
disease progression.
Table 3 Demographic characteristics of patients with nonradiographic axial spondyloarthritis across geographic regions
Africa (n = 33) Europe (n = 88) Asia (n = 140) p Value
Sex 0.609
Male, n (%) 18 (54.55 %) 57 (64.77 %) 90 (64.29 %)
95 % CI (37.45–71.64) (54.73–74.82) (56.30–72.27)
Female (%) 15 (45.45 %) 31 (35.23 %) 50 (35.71 %)
95 % CI (28.36–62.55) (25.18–45.27) (27.73–43.70)
Age, years mean ± SD 36.67 ± 10.73 36.02 ± 10.56 33.24 ± 9.26 0.035
BMI category 0.21
Underweight, n (%) 1 (3.03 %) 4 (4.55 %) 7 (5.00 %)
95 % CI (0.00–8.92) (0.17–8.93) (1.37–8.63)
Normal weight, n (%) 16 (48.48 %) 51 (57.95 %) 81 (57.86 %)
95 % CI (31.32–65.65) (47.57–68.34) (49.62–66.09)
Overweight, n (%) 13 (39.39 %) 19 (21.59 %) 44 (31.43 %)
95 % CI (22.61–56.17) (12.94–30.24) (23.69–39.17)
Obese, n (%) 2 (6.06 %) 14 (15.91 %) 7 (5.00 %)
95 % CI (0.00–14.25) (8.22–23.6) (1.37–8.63)
Unknown, n (%) 1 (3.03 %) 0 (0.00 %) 1 (0.71 %)
95 % CI (0.00–8.92) – (0.00–2.12)
Years since CLBP presentation 0.462
Number of patients 29 74 124
Mean ± SD, years 8.02 ± 10.01 6.68 ± 9.33 5.67 ± 5.70
Age of IBP onset 0.115
Number of patients 33 87 139
Mean ± SD, years 28.4 ± 8.7 28.3 ± 6.5 27.1 ± 7.3
BMI body mass index, CLBP chronic low back pain
The p values represent the omnibus statistical comparison of percentages (or means) across regions based on the chi-square (or F-test) values
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Limitations
Limitations of this epidemiological study include the use
of a single assessment with a questionnaire and CRF that
may not adequately capture a comprehensive medical
history for a particular patient. It is also important to
mention that this was an observational study, so not all
patients had complete information available. This could
have affected the classification of patients and therefore
Table 4 Clinical characteristics and HLA-B27 test results of patients with nonradiographic axial spondyloarthritis, ankylosing spondylitis,
and other inflammatory back pain
Total (N = 914) nr-axSpA (n = 266) AS (n = 491) Other IBP (n = 157) p Value
HLA-B27 test results (when available) <0.001
Positive, n (%) 397 (72.98 %) 135 (71.43 %) 250 (82.78 %) 12 (22.64 %)
Negative, n (%) 147 (27.02 %) 54 (28.57 %) 52 (17.22 %) 41 (77.36 %)
Years from IBP to SpA diagnosis 0.747
Number of patients 179 98 27 54
Mean ± SD, years 5.40 ± 7.98 5.21 ± 7.69 6.48 ± 8.53 5.19 ± 8.32
Family history of SpA <0.001
Yes, n (%) 220 (24.07 %) 70 (26.32 %) 132 (26.88 %) 18 (11.46 %)
No, n (%) 650 (71.12 %) 180 (67.67 %) 343 (69.86 %) 127 (80.89 %)
Results not available, n (%) 44 (4.81 %) 16 (6.02 %) 16 (3.26 %) 12 (7.64 %)
Family history of SpA (excluding missing) <0.001
Yes, n (%) 220 (25.29 %) 70 (28.00 %) 132 (27.79 %) 18 (12.41 %)
No, n (%) 650 (74.71 %) 180 (72.00 %) 343 (72.21 %) 127 (87.59 %)
NSAID response 0.125
Positive, n (%) 657 (71.88 %) 183 (68.80 %) 358 (72.91 %) 116 (73.89 %)
Negative, n (%) 231 (25.27 %) 72 (27.07 %) 125 (25.46 %) 34 (21.66 %)
Results not available, n (%) 26 (2.84 %) 11 (4.14 %) 8 (1.63 %) 7 (4.46 %)
Most recent CRP value 0.146
Number of patients 767 226 421 120
Mean ± SD, mg/L 16.7 ± 26.0 15.8 ± 28.2 18.2 ± 25.3 13.2 ± 23.5
Most recent CRP level <0.001
Not elevated (<3.5 mg/L), n (%) 219 (23.96 %) 72 (27.07 %) 96 (19.55 %) 51 (32.48 %)
Elevated (≥3.5 mg/L), n (%) 548 (59.96 %) 154 (57.89 %) 325 (66.19 %) 69 (43.95 %)
Results not available, n (%) 147 (16.08 %) 40 (15.04 %) 70 (14.26 %) 37 (23.57 %)
Most recent CRP level (excluding missing) <0.001
Not elevated (<3.5 mg/L), n (%) 219 (28.55 %) 72 (31.86 %) 96 (22.80 %) 51 (42.50 %)
Elevated (≥3.5 mg/L), n (%) 548 (71.45 %) 154 (68.14 %) 325 (77.20 %) 69 (57.50 %)
Most recent ESR value 0.009
Number of patients 846 252 464 130
Mean ± SD, mm/h 29.0 ± 23.6 26.8 ± 23.9 31.2 ± 23.6 25.3 ± 22.8
Most recent ESR level <0.001
Not elevated (<28 mm/h), n (%) 482 (52.74 %) 158 (59.40 %) 237 (48.27 %) 87 (55.41 %)
Elevated (≥28 mm/h), n (%) 364 (39.82 %) 94 (35.34 %) 227 (46.23 %) 43 (27.39 %)
Results not available, n (%) 68 (7.44 %) 14 (5.26 %) 27 (5.50 %) 27 (17.20 %)
Most recent ESR level (excluding missing) <0.001
Not elevated (<28 mm/h), n (%) 482 (56.97 %) 158 (62.70 %) 237 (51.08 %) 87 (66.92 %)
Elevated (≥28 mm/h), n (%) 364 (43.03 %) 94 (37.30 %) 227 (48.92 %) 43 (33.08 %)
Abbreviations: AS ankylosing spondylitis, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HLA-B27 human leukocyte antigen B27, IBP inflammatory back
pain, nr-axSpA nonradiographic axial spondyloarthritis, NSAID nonsteroidal anti-inflammatory drug, SpA spondyloarthritis
The p values represent the omnibus statistical comparison of percentages (or means) across IBP groups based on the chi-square values
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the prevalence estimates. For example, because a positive
HLA-B27 test is one way to classify a patient as having nr-
axSpA instead of other IBP, missing HLA-B27 data would
underestimate the number of nr-axSpA patients relative
to other IBP patients. Another limitation was the lack of
available information on the other IBP group. Although
this group also had poor outcomes based on the PRO
data, the explanation for this finding is unclear without
knowing more about the composition of the other IBP
group. Patient surveys were administered only to patients
who were diagnosed with AS and nr-axSpA, so patients
who were not diagnosed with either condition, even if they
met the appropriate classification criteria, did not provide
PRO data. The external validity of the study is dependent
on the extent to which patients at the selected rheumatol-
ogy practices are representative of all IBP patients in these
countries. Because these sites were selected for being
major centers for the treatment of SpA, it is possible the
patients who are managed by these sites are fundamentally
different (e.g., more severe disease).
Table 5 Clinical characteristics and HLA-B27 test results of patients with nonradiographic axial spondyloarthritis across geographic
regions
Africa (n = 33) Europe (n = 88) Asia (n = 140) p Value
Laboratory-confirmed SpA (HLA-B27) 0.062
Positive, n (%) 15 (45.45 %) 56 (63.64 %) 61 (43.57 %)
Negative, n (%) 6 (18.18 %) 10 (11.36 %) 37 (26.43 %)
Results not available, n (%) 12 (36.36 %) 22 (25.00 %) 42 (30.00 %)
Laboratory-confirmed SpA (excluding missing) (HLA-B27) 0.019
Positive, n (%) 15 (71.43 %) 56 (84.85 %) 61 (62.24 %)
Negative, n (%) 6 (28.57 %) 10 (15.15 %) 37 (37.76 %)
Family history of SpA 0.231
Yes, n (%) 9 (27.27 %) 18 (20.45 %) 43 (30.71 %)
No, n (%) 22 (66.67 %) 67 (76.14 %) 86 (61.43 %)
Results not available, n (%) 2 (6.06 %) 3 (3.41 %) 11 (7.86 %)
Family history of SpA (excluding missing) 0.125
Yes, n (%) 9 (29.03 %) 18 (21.18 %) 43 (33.33 %)
No, n (%) 22 (70.97 %) 67 (78.82 %) 86 (66.67 %)
NSAID response 0.264
Positive, n (%) 22 (66.67 %) 64 (72.73 %) 93 (66.43 %)
Negative, n (%) 7 (21.21 %) 22 (25.00 %) 42 (30.00 %)
Results not available, n (%) 4 (12.12 %) 2 (2.27 %) 5 (3.57 %)
Most recent CRP level 0.214
Not elevated (<3.5 mg/L), n (%) 10 (30.30 %) 21 (23.86 %) 37 (26.43 %)
Elevated (≥3.5 mg/L), n (%) 18 (54.55 %) 55 (62.50 %) 80 (57.14 %)
Results not available, n (%) 5 (15.15 %) 12 (13.64 %) 23 (16.43 %)
Most recent CRP level (excluding missing) 0.104
Not elevated (<3.5 mg/L), n (%) 10 (35.71 %) 21 (27.63 %) 37 (31.62 %)
Elevated (≥3.5 mg/L), n (%) 18 (64.29 %) 55 (72.37 %) 80 (68.38 %)
Most recent ESR level <0.001
Not elevated (<28 mm/h), n (%) 20 (60.61 %) 66 (75.00 %) 69 (49.29 %)
Elevated (≥28 mm/h), n (%) 9 (27.27 %) 17 (19.32 %) 66 (47.14 %)
Results not available, n (%) 4 (12.12 %) 5 (5.68 %) 5 (3.57 %)
Most recent ESR level (excluding missing) <0.001
Not elevated (<28 mm/h), n (%) 20 (68.97 %) 66 (79.52 %) 69 (51.11 %)
Elevated (≥28 mm/h), n (%) 9 (31.03 %) 17 (20.48 %) 66 (48.89 %)
Abbreviations: CRP C-reactive protein, ESR erythrocyte sedimentation rate, HLA-B27 human leukocyte antigen B27, NSAID nonsteroidal anti-inflammatory drug,
SpA spondyloarthritis
The p values represent the omnibus statistical comparison of percentages (or means) across regions based on the chi-square values
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Conclusions
The results of the present study suggest that approxi-
mately one-third of patients with IBP meet ASAS cri-
teria for nr-axSpA. Patients with nr-axSpA, as compared
with patients with AS, tend to be younger and experi-
ence symptoms for a shorter time before diagnosis. The
PRO data suggest that the overall disease burden in nr-
axSpA is substantial and similar to that in AS, with both
groups of patients experiencing inadequate disease con-
trol. These findings show the continued need for early
diagnosis of nr-axSpA across Latin America, Europe,
Africa, and Asia. These findings also emphasize the im-
portance of early initiation of available treatment options
to slow disease progression and improve patient well-
being in these patients’ most productive years of life.
Abbreviations
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